c-erbB-2

Mouse IgG1

Human c-erbB-2 aa. 1242-1255

C-erbB-2 (also known as HER2/neu), a 185 kDa transmembrane glycoprotein, is a member of the type 1 growth factor receptor subfamily which also includes c-erbB-3, c-erbB-4 and the epidermal growth factor receptor (EGFR), also known as c-erbB-1. Members of this receptor subfamily mediate the proliferation and differentiation of normal cells. They have a common structure consisting of an extracellular domain, a transmembrane region, and a cytoplasmic sequence. The extracellular regions contain two cysteine-rich domains, and the intracellular regions have sequence homology to known tyrosine kinases. C-erbB-2 reactivity has been detected in proximal kidney tubules, mucosal epithelium in the gastrointestinal tract, and squamous epithelium in skin. Most normal adult tissues show little or no reactivity with antibodies against c-erbB-2. However, c-erbB-2 is overexpressed in many human breast, stomach, ovary and bladder carcinomas. EGFR, c-erbB-3 and c-erbB-4 are also overexpressed in various human tumor cells, and it is thought that aberrant activation of type 1 growth factor kinase activities may contribute to tumor progression. The antibody 3B5 recognizes human c-erbB-2.  A synthetic peptide corresponding to amino acids 1242-1255 (TAENPEYLGLDVPV) in the C-terminal domain of human c-erbB-2 was used as immunogen.

3B5 C-erbB-2 (also known as HER2/neu), a 185 kDa transmembrane glycoprotein, is a member of the type 1 growth factor receptor subfamily which also includes c-erbB-3, c-erbB-4 and the epidermal growth factor receptor (EGFR), also known as c-erbB-1. Members of this receptor subfamily mediate the proliferation and differentiation of normal cells. They have a common structure consisting of an extracellular domain, a transmembrane region, and a cytoplasmic sequence. The extracellular regions contain two cysteine-rich domains, and the intracellular regions have sequence homology to known tyrosine kinases. C-erbB-2 reactivity has been detected in proximal kidney tubules, mucosal epithelium in the gastrointestinal tract, and squamous epithelium in skin. Most normal adult tissues show little or no reactivity with antibodies against c-erbB-2. However, c-erbB-2 is overexpressed in many human breast, stomach, ovary and bladder carcinomas. EGFR, c-erbB-3 and c-erbB-4 are also overexpressed in various human tumor cells, and it is thought that aberrant activation of type 1 growth factor kinase activities may contribute to tumor progression. The antibody 3B5 recognizes human c-erbB-2.  A synthetic peptide corresponding to amino acids 1242-1255 (TAENPEYLGLDVPV) in the C-terminal domain of human c-erbB-2 was used as immunogen.

Mouse IgG1

克隆 3B5 (RUO)

0.5 mg/ml

Western blot (Routinely Tested), Immunohistochemistry-paraffin (Tested During Development), Immunohistochemistry-frozen, Immunoprecipitation (Reported)

Human (QC Testing)

CD340 (HER2/ErbB2)

Aqueous buffered solution containing ≤0.09% sodium azide.

研发参考(10) 1. Carraway KL 3rd, Cantley LC. A neu acquaintance for erbB3 and erbB4: a role for receptor heterodimerization in growth signaling. Cell. 1994; 78(1):5-8. (Biology). 2. Hancock MC, Langton BC, Chan T, et al. A monoclonal antibody against the c-erbB-2 protein enhances the cytotoxicity of cis-diamminedichloroplatinum against human breast and ovarian tumor cell lines. Cancer Res. 1991; 51(17):4575-4589. (Biology). 3. In: Hesketh R. The Oncogene Handbook. New York: Academic Press; 1994:485-509. 4. Martinazzi M, Crivelli F, Zampatti C, Martinazzi S. Relationships between epidermal growth factor receptor (EGF-R) and other predictors of prognosis in breast carcinomas. An immunohistochemical study. Pathologica. 1993; 85(1100):637-644. (Clone-specific: Immunohistochemistry). 5. Meissner K, Riviere A, Haupt G, Loning T. Study of neu-protein expression in mammary Paget's disease with and without underlying breast carcinoma and in extramammary Paget's disease. Am J Pathol. 1990; 137(6):1305-1309. (Clone-specific: Immunohistochemistry). 6. Penault-Llorca F, Adelaide J, Houvenaeghel G, Hassoun J, Birnbaum D, Jacquemier J. Optimization of immunohistochemical detection of ERBB2 in human breast cancer: impact of fixation. J Pathol. 1994; 173(1):65-75. (Clone-specific: Immunohistochemistry). 7. Schwechheimer K, Laufle RM, Schmahl W, Knodlseder M, Fischer H, Hofler H. Expression of neu/c-erbB-2 in human brain tumors. Hum Pathol. 1994; 25(8):772-780. (Clone-specific: Immunohistochemistry). 8. Singleton TP, Niehans GA, Gu F, et al. Detection of c-erbB-2 activation in paraffin-embedded tissue by immunohistochemistry. Hum Pathol. 1992; 23(10):1141-1150. (Clone-specific: Immunohistochemistry). 9. Zhau HE, Zhang X, von Eschenbach AC, et al. Amplification and expression of the c-erb B-2/neu proto-oncogene in human bladder cancer. Mol Carcinog. 1990; 3(5):254-257. (Clone-specific: Immunohistochemistry, Western blot). 10. van de Vijver MJ, Peterse JL, Mooi WJ, et al. Neu-protein overexpression in breast cancer. Association with comedo-type ductal carcinoma in situ and limited prognostic value in stage II breast cancer. N Engl J Med. 1988; 319(19):1239-1245. (Clone-specific: Immunohistochemistry, Immunoprecipitation).